eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | tuberous sclerosis |
| Symptom | C1860715|giant cell astrocytoma |
| Sentences | 34 |
| PubMedID- 23404211 | It is approved for the treatment of patients with progressive neuroendocrine tumors of pancreatic origin, advanced renal cell carcinoma, and subependymal giant cell astrocytoma associated with tuberous sclerosis . |
| PubMedID- 20422196 | The diagnosis and treatment of subependymal giant cell astrocytoma combined with tuberous sclerosis. |
| PubMedID- 24708766 | The rapamycin analogs cci-779 (temsirolimus) and rad001 (everolimus) are approved for the clinical treatment of advanced renal cell carcinoma , progressive neuroendocrine tumors of pancreatic origin , subependymal giant cell astrocytoma associated with tuberous sclerosis , and more recently for postmenopausal women with advanced hormone receptor-positive, her2-negative breast cancer in combination with the aromatase inhibitor exemestane . |
| PubMedID- 25557360 | Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis. |
| PubMedID- 24244540 | Everolimus has been approved for second-line therapy of patients with renal cell carcinoma after failure of treatment with sunitinib and for the treatment of papillary renal carcinoma, pancreatic neuroendocrine tumor, some types of breast cancer, and subependymal giant cell astrocytoma associated with tuberous sclerosis –. |
| PubMedID- 23231513 | In patients with subependymal giant cell astrocytomas (segas) associated with tuberous sclerosis complex who are not candidates for surgery, single-agent everolimus has demonstrated the ability to significantly reduce sega volume with good tolerability. |
| PubMedID- 22136276 | Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 25682485 | Conclusion: everolimus is a promising pharmacological approach to treat clinically significant inoperable cardiac rhabdomyomas or subependymal giant cell astrocytoma associated with tuberous sclerosis complex during the neonatal period. |
| PubMedID- 23183057 | The outcome of surgical management of subependymal giant cell astrocytoma in tuberous sclerosis complex. |
| PubMedID- 26381530 | Objective: to analyze the cumulative efficacy and safety of everolimus in treating subependymal giant cell astrocytomas (sega) associated with tuberous sclerosis complex (tsc) from an open-label phase ii study (nct00411619). |
| PubMedID- 23567018 | Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 24105488 | Subependymal giant cell astrocytomas in patients with tuberous sclerosis complex: considerations for surgical or pharmacotherapeutic intervention. |
| PubMedID- 23158522 | Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (exist-1): a multicentre, randomised, placebo-controlled phase 3 trial. |
| PubMedID- 25143481 | Everolimus treatment for an early infantile subependymal giant cell astrocytoma with tuberous sclerosis complex. |
| PubMedID- 25456370 | Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised exist-1 study. |
| PubMedID- 23788851 | On the other hand, the mtor inhibitor rapamycin is found to be useful in tuberous sclerosis patients with subependymal giant cell astrocytomas. |
| PubMedID- 23391693 | Management of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc): clinical recommendations. |
| PubMedID- 25227171 | Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. |
| PubMedID- 23138436 | The authors describe a rare case of subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex that presented with intratumoral bleeding with extension to the ventricles. |
| PubMedID- 24667738 | The burden of subependymal giant cell astrocytomas associated with tuberous sclerosis complex: results of a patient and caregiver survey. |
| PubMedID- 25493579 | Subependymal giant cell astrocytoma associated with tuberous sclerosis complex - pharmacological treatment using mtor inhibitors. |
| PubMedID- 20133820 | Novel proteins regulated by mtor in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications. |
| PubMedID- 23743818 | Recent studies support the use of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis and suggest it might represent a disease-modifying treatment for other aspects of tuberous sclerosis. |
| PubMedID- 24056156 | Specific inhibitors of this pathway have been shown to reduce the volume of subependymal giant cell astrocytomas associated with tuberous sclerosis. |
| PubMedID- 21297924 | From the bench to the bedside: everolimus for subependymal giant cell astrocytomas in tuberous sclerosis complex, optic nerve regeneration, targeted cytotoxins for gliomas. |
| PubMedID- 24756805 | Everolimus has been approved by the fda and the ema for the treatment of advanced renal cell carcinoma (rcc), subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis (tsc), pancreatic neuroendocrine tumors (pnet), in combination with exemestane in advanced hormone-receptor (hr)-positive, her2-negative breast cancer. |
| PubMedID- 23686401 | Everolimus is a mammalian target of rapamycin (mtor) inhibitor approved for the treatment of advanced renal cell carcinoma, pancreatic neuroendocrine tumors, subependymal giant cell astrocytoma associated with tuberous sclerosis complex, renal angiomyolipoma and tuberous sclerosis complex, and, in combination with exemestane, for hormone receptor-positive her2-negative advanced breast cancer after failure of treatment with letrozole or anastrozole. |
| PubMedID- 20643042 | Subependymal giant cell astrocytoma in tuberous sclerosis complex. |
| PubMedID- 22234227 | Hemorrhagic subependymal giant cell astrocytoma in a patient with tuberous sclerosis: case report and review of the literature. |
| PubMedID- 24507694 | Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. |
| PubMedID- 24276039 | Background: brain subependymal giant cell astrocytomas (segas) in patients with tuberous sclerosis have been reported to respond to everolimus. |
| PubMedID- 23325902 | Objective: to report long-term efficacy and safety data for everolimus for the treatment of subependymal giant cell astrocytoma (sega) in patients with tuberous sclerosis complex (tsc). |
| PubMedID- 22805244 | Everolimus for tumor recurrence after surgical resection for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. |
| PubMedID- 20887114 | Rapamycin as an alternative to surgical treatment of subependymal giant cell astrocytomas in a patient with tuberous sclerosis complex. |
Page: 1